Video

Dr. Eng on Roles of Regorafenib and TAS-102 in CRC Treatment

Author(s):

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ongoing roles of regorafenib (Stivarga) and TAS-102 (Lonsurf) in colorectal cancer (CRC) treatment.

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ongoing roles of regorafenib (Stivarga) and TAS-102 (Lonsurf) in colorectal cancer (CRC) treatment.

The question of choosing between regorafenib and TAS-102 is one that comes up frequently in clinical practice, Eng explains. Regorafenib may be associated with increased liver function tests; therefore, for a patient with significant tumor burden in the live, this agent may not be the primary treatment choice. Additionally, regorafenib is an angiogeneic agent, so if physicians are concerned about patients' blood pressure, risk of stroke, or potential risk of bowel obstruction, TAS-102 may be a more appropriate choice.

However, TAS-102 results in increased myelosuppression. In this case, physicians can adjust a patients' dosing schedule or pegfilgrastim (Neulasta). Both regorafenib and TAS-102 are oral agents and require close follow-up of agents, Eng adds.

<<< View more from the 2017 Chemotherapy Foundation Symposium

Related Videos
Aparna Parikh, MD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Aparna Parikh, MD, associate professor, medicine, Harvard Medical School; assistant in medicine, Hematology, Oncology, Massachusetts General Hospital; attending oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, the Henri and Belinda Termeer Center for Targeted Therapies
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on data for neoadjuvant nivolumab plus ipilimumab in dMMR colon cancer.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.